These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 9426973)

  • 1. Soluble interferon-gamma receptor and interferon-gamma in patients undergoing allogeneic bone marrow transplantation for hematological malignancies.
    Toren A; Barak V; Novick D; Nagler A
    Cytokines Cell Mol Ther; 1997 Sep; 3(3):153-8. PubMed ID: 9426973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-2 inhibits early increases in serum gamma interferon levels associated with graft-versus-host-disease.
    Szebeni J; Wang MG; Pearson DA; Szot GL; Sykes M
    Transplantation; 1994 Dec; 58(12):1385-93. PubMed ID: 7809932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble interleukin-6 receptors in hematology patients undergoing bone marrow transplantation.
    Toren A; Novick D; Or R; Ackerstein A; Slavin S; Nagler A
    Transplantation; 1996 Jul; 62(1):138-42. PubMed ID: 8693533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated inflammatory cytokine levels in bone marrow graft rejection.
    Nagler A; Or R; Nisman B; Kalickman I; Slavin S; Barak V
    Transplantation; 1995 Nov; 60(9):943-8. PubMed ID: 7491698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of low histidine rich glycoprotein plasma levels with the occurrence of acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Mauz-Körholz C; Körholz D; Burdach S
    J Lab Clin Med; 1995 Aug; 126(2):144-50. PubMed ID: 7636387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble IL-6 receptors (sIL-6R) in hematological patients receiving immunotherapy with IL-2/IFN-alpha or donor lymphocytes following bone marrow transplantation.
    Toren A; Novick D; Ackerstein A; Or R; Slavin S; Nagler A
    Bone Marrow Transplant; 1996 Oct; 18(4):721-4. PubMed ID: 8899186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A possible association between the presence of interleukin-4-secreting cells and a reduction in the risk of acute graft-versus-host disease.
    Takabayashi M; Kanamori H; Takasaki H; Yamaji S; Koharazawa H; Taguchi J; Tomita N; Fujimaki K; Fujisawa S; Maruta A; Ishigatsubo Y
    Exp Hematol; 2005 Feb; 33(2):251-7. PubMed ID: 15676220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation.
    Remberger M; Ringdén O
    Transplantation; 1995 Dec; 60(11):1293-9. PubMed ID: 8525524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-18 binding protein in acute graft versus host disease and engraftment following allogeneic peripheral blood stem cell transplants.
    Zecchina G; Novick D; Rubinstein M; Barak V; Dinarello C; Nagler A
    J Hematother Stem Cell Res; 2001 Dec; 10(6):769-76. PubMed ID: 11798503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of interleukin-12 in the development of acute graft-versus-host disease in bone marrow transplant patients.
    Yabe M; Yabe H; Hattori K; Shimizu T; Matsumoto M; Morimoto T; Yasuda Y; Inoue H; Kato S; Nishimura T
    Bone Marrow Transplant; 1999 Jul; 24(1):29-34. PubMed ID: 10435731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease.
    Imamura M; Hashino S; Kobayashi H; Kubayashi S; Hirano S; Minagawa T; Tanaka J; Fujii Y; Kobayashi M; Kasai M
    Bone Marrow Transplant; 1994 Jun; 13(6):745-51. PubMed ID: 7920309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
    J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation.
    Nagler A; Bishara A; Brautbar C; Barak V
    Cytokines Cell Mol Ther; 1998 Sep; 4(3):161-7. PubMed ID: 9825841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time course of interferon-gamma production deficiency after autologous and allogeneic stem cell transplantation for malignancies.
    Hanenberg H; Dilloo D; Laws HJ; Zessack N; Heyll A; Burdach S
    Exp Hematol; 1995 Dec; 23(14):1543-52. PubMed ID: 8542945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.
    Min CK; Eom KS; Lee S; Kim DW; Lee JW; Min WS; Kim CC
    Bone Marrow Transplant; 2001 May; 27(9):999-1005. PubMed ID: 11436112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients.
    Tanimoto TE; Yamaguchi T; Tanaka Y; Saito A; Tajima K; Karasuno T; Kasai M; Kishi K; Mori T; Maseki N; Morishima S; Miyakoshi S; Kasai M; Ohno Y; Kim SW; Numata A; Kami M; Takaue Y; Mori S; Harada M
    Br J Haematol; 2004 May; 125(4):480-93. PubMed ID: 15142119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine gene expression by concanavalin A-stimulated peripheral mononuclear cells after bone marrow transplantation: an indicator of immunological abnormality due to chronic graft-versus-host disease.
    Tanaka J; Imamura M; Kasai M; Zhu X; Kobayashi S; Imai K; Hashino S; Higa T; Sakurada K; Miyazaki T
    Bone Marrow Transplant; 1994 Nov; 14(5):695-701. PubMed ID: 7889002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TH1/TH2 cytokines and soluble CD30 levels in kidney allograft patients with donor bone marrow cell infusion.
    Solgi G; Amirzagar AA; Pourmand G; Mehrsai AR; Taherimahmoudi M; Baradaran N; Nicknam MH; Ebrahimi Rad MR; Saraji A; Asadpoor AA; Moheiydin M; Nikbin B
    Transplant Proc; 2009 Sep; 41(7):2800-4. PubMed ID: 19765439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
    Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
    Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune modulation in autologous bone marrow transplantation: cyclosporine and gamma-interferon trial.
    Vogelsang G; Bitton R; Piantadosi S; Altomonte V; Horn T; Jones R; Miller C; Marcellus D; Abrams R; Hess A
    Bone Marrow Transplant; 1999 Sep; 24(6):637-40. PubMed ID: 10490729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.